Product data
- Strength
- 1%
- Dosage form
- Cream
- Dosage-form group
- Topical
- Therapeutic area
- Antiparasitic
- Market
- EU
- Exclusivity signed
- Netherlands, Germany, Norway, Sweden, Finland, Ukraine, Czech Republic, Australia, Denmark, Spain, UK, Poland, Austria
- Status
- Dossier target · Apr 2027
- Development status
- Pilot bio in progress
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23